Journal of Antimicrobial Chemotherapy (1999) 44, 749-759
© 1999 The British Society for Antimicrobial Chemotherapy
Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 19971998
a MRL Pharmaceutical Services, Brentwood, TN, USA b Utrecht, The Netherlands c 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171-4603 d Ortho-McNeil Pharmaceutical, Raritan, NJ, USA
A national antimicrobial resistance surveillance study was conducted from December
1997 to May 1998 to determine the prevalence of antimicrobial resistance in 6620 clinical
isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. In this centralized study, which involved 163 institutions located in
43 states, we determined MICs for representatives of five antimicrobial classes: ß-lactams
(penicillin, co-amoxiclav, cefuroxime, ceftriaxone), macrolides (azithromycin, clarithromycin),
co-trimoxazole, glycopeptides (vancomycin) and fluoroquinolones (levofloxacin). In most S.
pneumoniae isolates, all antimicrobials were to be found active, but amongst
penicillin-resistant isolates (MICs
2 mg/L), resistance to other ß-lactams, macrolides
and co-trimoxazole was common. For vancomycin and levofloxacin, however, activity was not
associated with penicillin resistance. The prevalence of penicillin-nonsusceptible (intermediate
and resistant) pneumococci was highest in the South Atlantic (44%) and East South Central
(43%) regions and lowest in the Mid-Atlantic (28%) and New England (28%) regions.
Resistance to ß-lactams, macrolides and co-trimoxazole was more commonly found amongst
respiratory isolates than blood isolates and in strains from patients
12 years old than from
older patients. ß-lactamase, which was detected in 33% of H. influenzae and 92%
of M. catarrhalis strains, did not affect the activity of the ß-lactams under study
other than ampicillin. Certain agents, such as vancomycin and the fluoroquinolones, remain
highly active, and well-designed surveillance systems that monitor MIC distributions would be
needed to detect a potential for reduced susceptibility. In addition, surveillance programmes
should be designed to collect information about associated resistance as well as differences in
prevalence associated with region, specimen source and patient age.
* Corresponding author: Tel: +1-703-480-2500; Fax +1-703-480-2670; E-mail: dsahm{at}thetsn.com
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
J. A. Starr, G. W. Fox, and J. K. Clayton Streptococcus pneumoniae: An Update on Resistance Patterns in the United States Journal of Pharmacy Practice, October 1, 2008; 21(5): 363 - 370. [Abstract] [PDF] |
||||
![]() |
A. C. Fluit, A. Florijn, J. Verhoef, and D. Milatovic Susceptibility of European {beta}-lactamase-positive and -negative Haemophilus influenzae isolates from the periods 1997/1998 and 2002/2003 J. Antimicrob. Chemother., July 1, 2005; 56(1): 133 - 138. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Oteo, E. Lazaro, F. J. de Abajo, F. Baquero, J. Campos, and Spanish Members of the European Antimicrobial Resi Trends in Antimicrobial Resistance in 1,968 Invasive Streptococcus pneumoniae Strains Isolated in Spanish Hospitals (2001 to 2003): Decreasing Penicillin Resistance in Children's Isolates J. Clin. Microbiol., December 1, 2004; 42(12): 5571 - 5577. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Morikawa, M. Kitazato, J. Mitsuyama, S. Mizunaga, S. Minami, and Y. Watanabe In Vitro Activities of Piperacillin against {beta}-Lactamase-Negative Ampicillin-Resistant Haemophilus influenzae Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1229 - 1234. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Low, M. E. Pichichero, and U. B. Schaad Optimizing Antibacterial Therapy for Community-Acquired Respiratory Tract Infections in Children in an Era of Bacterial Resistance Clinical Pediatrics, March 1, 2004; 43(2): 135 - 151. [Abstract] [PDF] |
||||
![]() |
R. Canton, M. Morosini, M. C. Enright, and I. Morrissey Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme J. Antimicrob. Chemother., December 1, 2003; 52(6): 944 - 952. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J Schentag, A. K Meagher, and A. Forrest Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates: Part 1: In Vitro and Animal Models Ann. Pharmacother., September 1, 2003; 37(9): 1287 - 1298. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-C. Galan, M.-I. Morosini, M.-R. Baquero, M. Reig, and F. Baquero Haemophilus influenzae blaROB-1 Mutations in Hypermutagenic {Delta}ampC Escherichia coli Conferring Resistance to Cefotaxime and {beta}-Lactamase Inhibitors and Increased Susceptibility to Cefaclor Antimicrob. Agents Chemother., August 1, 2003; 47(8): 2551 - 2557. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Karlowsky, C. Thornsberry, I. A. Critchley, M. E. Jones, A. T. Evangelista, G. J. Noel, and D. F. Sahm Susceptibilities to Levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Clinical Isolates from Children: Results from 2000-2001 and 2001-2002 TRUST Studies in the United States Antimicrob. Agents Chemother., June 1, 2003; 47(6): 1790 - 1797. [Abstract] [Full Text] [PDF] |
||||
![]() |
B D Gaynor, K A Holbrook, J P Whitcher, S O Holm, H C Jha, J S P Chaudhary, R C Bhatta, and T Lietman Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year Br J Ophthalmol, February 1, 2003; 87(2): 147 - 148. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Jones, J. A. Karlowsky, R. Blosser-Middleton, I. Critchley, C. Thornsberry, and D. F. Sahm Relationship between Antibiotic Resistance in Streptococcus pneumoniae and That in Haemophilus influenzae: Evidence for Common Selective Pressure Antimicrob. Agents Chemother., September 1, 2002; 46(9): 3106 - 3107. [Full Text] [PDF] |
||||
![]() |
M. E. Jones, J. A. Karlowsky, R. Blosser-Middleton, I. A. Critchley, E. Karginova, C. Thornsberry, and D. F. Sahm Longitudinal Assessment of Antipneumococcal Susceptibility in the United States Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2651 - 2655. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Pihlajamaki, T. Kaijalainen, P. Huovinen, J. Jalava, and the Finnish Study Group for Antimicrobial Resistan Rapid increase in macrolide resistance among penicillin non-susceptible pneumococci in Finland, 1996-2000 J. Antimicrob. Chemother., May 1, 2002; 49(5): 785 - 792. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Karlowsky, I. A. Critchley, R. S. Blosser-Middleton, E. A. Karginova, M. E. Jones, C. Thornsberry, and D. F. Sahm Antimicrobial Surveillance of Haemophilus influenzae in the United States during 2000-2001 Leads to Detection of Clonal Dissemination of a {beta}-Lactamase-Negative and Ampicillin-Resistant Strain J. Clin. Microbiol., March 1, 2002; 40(3): 1063 - 1066. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. A. Critchley, J. A. Karlowsky, D. C. Draghi, M. E. Jones, C. Thornsberry, K. Murfitt, and D. F. Sahm Activities of Faropenem, an Oral {beta}-Lactam, against Recent U.S. Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Antimicrob. Agents Chemother., February 1, 2002; 46(2): 550 - 555. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. F. Sahm, C. Thornsberry, D. C. Mayfield, M. E. Jones, and J. A. Karlowsky In Vitro Activities of Broad-Spectrum Cephalosporins against Nonmeningeal Isolates of Streptococcus pneumoniae: MIC Interpretation Using NCCLS M100-S12 Recommendations J. Clin. Microbiol., February 1, 2002; 40(2): 669 - 674. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Verduin, C. Hol, A. Fleer, H. van Dijk, and A. van Belkum Moraxella catarrhalis: from Emerging to Established Pathogen Clin. Microbiol. Rev., January 1, 2002; 15(1): 125 - 144. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Fass and J. Barnishan Comparison of antimicrobial in vitro activities against Streptococcus pneumoniae independent of MIC susceptibility breakpoints using MIC frequency distribution curves, scattergrams and linear regression analyses J. Antimicrob. Chemother., November 1, 2001; 48(5): 609 - 615. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. L. Ho, R. W. H. Yung, D. N. C. Tsang, T. L. Que, M. Ho, W. H. Seto, T. K. Ng, W. C. Yam, and W. W. S. Ng Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000 J. Antimicrob. Chemother., November 1, 2001; 48(5): 659 - 665. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Roychoudhury, T. L. Twinem, K. M. Makin, E. J. McIntosh, B. Ledoussal, and C. E. Catrenich Activity of non-fluorinated quinolones (NFQs) against quinolone-resistant Escherichia coli and Streptococcus pneumoniae J. Antimicrob. Chemother., July 1, 2001; 48(1): 29 - 36. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. File Jr, B. Schlemmer, J. Garau, M. Cupo, C. Young, and the 049 Clinical Study Group Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin J. Antimicrob. Chemother., July 1, 2001; 48(1): 67 - 74. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Coyle, G. W. Kaatz, and M. J. Rybak Activities of Newer Fluoroquinolones against Ciprofloxacin-Resistant Streptococcus pneumoniae Antimicrob. Agents Chemother., June 1, 2001; 45(6): 1654 - 1659. [Abstract] [Full Text] |
||||
![]() |
D. F. Sahm, J. A. Karlowsky, L. J. Kelly, I. A. Critchley, M. E. Jones, C. Thornsberry, Y. Mauriz, and J. Kahn Need for Annual Surveillance of Antimicrobial Resistance in Streptococcus pneumoniae in the United States: 2-Year Longitudinal Analysis Antimicrob. Agents Chemother., April 1, 2001; 45(4): 1037 - 1042. [Abstract] [Full Text] |
||||
![]() |
M. H. Gotfried, L. H. Danziger, and K. A. Rodvold Steady-State Plasma and Intrapulmonary Concentrations of Levofloxacin and Ciprofloxacin in Healthy Adult Subjects Chest, April 1, 2001; 119(4): 1114 - 1122. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Oteo, J. I. Alos, and J. L. Gomez-Garces Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: a multicentre surveillance study J. Antimicrob. Chemother., February 1, 2001; 47(2): 215 - 218. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. F. Sahm, I. A. Critchley, L. J. Kelly, J. A. Karlowsky, D. C. Mayfield, C. Thornsberry, Y. R. Mauriz, and J. Kahn Evaluation of Current Activities of Fluoroquinolones against Gram-Negative Bacilli Using Centralized In Vitro Testing and Electronic Surveillance Antimicrob. Agents Chemother., January 1, 2001; 45(1): 267 - 274. [Abstract] [Full Text] |
||||
![]() |
C. J. Henwood, D. M. Livermore, A. P. Johnson, D. James, M. Warner, A. Gardiner, and The Linezolid Study Group Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid J. Antimicrob. Chemother., December 1, 2000; 46(6): 931 - 940. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-S. Paek, M.-Y. Kim, C.-S. Lee, and H. Youn In Vitro and In Vivo Activities of LB 10827, a New Oral Cephalosporin, against Respiratory Pathogens Antimicrob. Agents Chemother., December 1, 2000; 44(12): 3272 - 3277. [Abstract] [Full Text] |
||||
![]() |
D. H. Wright, G. H. Brown, M. L. Peterson, and J. C. Rotschafer Application of fluoroquinolone pharmacodynamics J. Antimicrob. Chemother., November 1, 2000; 46(5): 669 - 683. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Jones, A. M. Staples, I. Critchley, C. Thornsberry, P. Heinze, H. D. Engler, and D. F. Sahm Benchmarking the In Vitro Activities of Moxifloxacin and Comparator Agents against Recent Respiratory Isolates from 377 Medical Centers throughout the United States Antimicrob. Agents Chemother., October 1, 2000; 44(10): 2645 - 2652. [Abstract] [Full Text] |
||||
![]() |
D. F. Sahm, D. E. Peterson, I. A. Critchley, and C. Thornsberry Analysis of Ciprofloxacin Activity against Streptococcus pneumoniae after 10 Years of Use in the United States Antimicrob. Agents Chemother., September 1, 2000; 44(9): 2521 - 2524. [Abstract] [Full Text] |
||||








